{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:12:43Z","timestamp":1783537963193,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Lymphoma is the most common hematologic malignancy diagnosed in active-duty service members (ADSMs). Service members treated for lymphoma often face uncertainty regarding their fitness for duty, which carries implications for individual careers and force readiness. In this retrospective, exploratory study we aimed to (1) determine the proportion of previously deployed ADSMs who deployed after a lymphoma diagnosis, and (2) characterize those deployments. Methods: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) cases diagnosed between 2001 and 2022 were identified from the Defense Health Agency Cancer Registry using International Classification of Diseases for Oncology, Third Edition histology codes. Deployment variables were obtained from the Defense Manpower Data Center. Analysis was restricted to service members who were on active duty at diagnosis and had a history of deployment; those who had never deployed were excluded. This study was exempt from full institutional review board review. Results: A total of 866 previously deployed ADSMs with lymphoma were identified (455 HL, 411 NHL). Of these, 119 (13.7%; 95% CI 11.6\u201316.2) deployed after their lymphoma diagnosis, including 86 of 455 with HL (18.9%; 95% CI 15.6\u201322.8) and 33 of 411 with NHL (8.0%; 95% CI 5.8\u201311.1). HL survivors were significantly more likely than NHL survivors to deploy after diagnosis (p &lt; 0.001). The mean interval from diagnosis to deployment was 5.1 years (SD 3.7) for HL and 4.5 years (SD 2.3) for NHL. As of 2022, all 119 individuals were alive at last follow-up. Conclusions: Among previously deployed ADSMs with lymphoma, roughly one in six deployed after their diagnosis and treatment, typically within five years. These findings indicate that deployment after lymphoma treatment is achievable for a significant subset of service members, highlighting both the success of cancer care in military treatment facilities and the favorable impact of modern oncologic care on operational readiness.<\/jats:p>","DOI":"10.3390\/jcm15145327","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:27:31Z","timestamp":1783531651000},"page":"5327","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Cure to Combat: Deployment After Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-1799","authenticated-orcid":false,"given":"Kyle","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathon M.","family":"Rolwes","sequence":"additional","affiliation":[{"name":"Department of Clinical Education, Montana College of Osteopathic Medicine, Rocky Vista University, Billings, MT 59106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Darmon","sequence":"additional","affiliation":[{"name":"Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"},{"name":"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Rendo","sequence":"additional","affiliation":[{"name":"Cancer Care Clinic, Wright Patterson Medical Center, Dayton, OH 45433, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-8869","authenticated-orcid":false,"given":"Joshua L.","family":"Fenderson","sequence":"additional","affiliation":[{"name":"U.S. Army Institute of Surgical Research, San Antonio, TX 78234, USA"},{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Dwarakanath","sequence":"additional","affiliation":[{"name":"David Grant USAF Medical Center, Fairfield, CA 94533, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-4983","authenticated-orcid":false,"given":"James K.","family":"Aden","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4903-4343","authenticated-orcid":false,"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-7760","authenticated-orcid":false,"given":"Christin B.","family":"DeStefano","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","first-page":"23","article-title":"Incident diagnoses of cancers in the active component and cancer-related deaths in the active and reserve components, U.S. Armed Forces, 2005\u20132014","volume":"23","author":"Lee","year":"2016","journal-title":"MSMR"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1093\/milmed\/usac297","article-title":"Cancer Incidence and Etiology in the Active Duty Population of U.S. Military","volume":"189","author":"Lovejoy","year":"2024","journal-title":"Mil. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yi, J.C., Walsh, C.A., Chow, E.J., Baker, K.S., Mendoza, J.A., and Cole, A. (2025). Primary care providers and their needs caring for cancer survivors: A qualitative study. J. Cancer Surviv.","DOI":"10.1007\/s11764-025-01852-y"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12185-025-03939-9","article-title":"Recent advances in understanding of pathogenesis and treatment development for diffuse large B-cell lymphoma and follicular lymphoma","volume":"121","author":"Ennishi","year":"2025","journal-title":"Int. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"Sattler, B. (2024). Recruit Medical Standards Are Out of Touch, U.S. Naval Institute\u2019s Proceedings. [3rd ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e3407","DOI":"10.1093\/milmed\/usad199","article-title":"Survival of U.S. Military Service Members with Lymphoma","volume":"188","author":"Ancira","year":"2023","journal-title":"Mil. Med."},{"key":"ref_9","unstructured":"Parker, K., Igielnik, R., Barroso, A., and Cilluffo, A. (2026, June 19). Deployment, Combat and Their Consequences. Pew Research Center. Available online: https:\/\/www.pewresearch.org\/social-trends\/2019\/09\/10\/deployment-combat-and-their-consequences\/."},{"key":"ref_10","unstructured":"U.S. Department of Defense (2010). Deployment-Limiting Medical Conditions for Service Members and DoD Civilian Employees, DoD Instruction 6490.07."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCO.0000000000001161","article-title":"All you need to know about survivorship in lymphoma in adults and AYA patients","volume":"37","author":"Stepanishyna","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1182\/blood-2023-181907","article-title":"Impact of Deployment on Survival in Military Personnel with Non-Hodgkin Lymphoma","volume":"142","author":"Sgrignoli","year":"2023","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2025031449","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"147","author":"Leaf","year":"2026","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood-2024-208412","article-title":"Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma","volume":"144","author":"Kuczmarski","year":"2024","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/lymphatics2040019","article-title":"Management of Secondary Immunodeficiency Following T-Cell-Engaging Immunotherapeutic Agents in B-Cell Non-Hodgkin Lymphoma: Implications for Early-Line Treatment Strategies","volume":"2","author":"Day","year":"2024","journal-title":"Lymphatics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/vox.70014","article-title":"International Forum on the Use of Irradiated Blood in Patients with Haematological Malignancy: Responses","volume":"120","author":"Zhang","year":"2025","journal-title":"Vox Sang."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/vox.70015","article-title":"International Forum on the Use of Irradiated Blood in Patients with Haematological Malignancy: Summary","volume":"120","author":"Zhang","year":"2025","journal-title":"Vox Sang."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/trf.70242","article-title":"Clarifying transfusion-associated graft-versus-host disease risk in modern Hodgkin lymphoma survivorship","volume":"66","author":"DeStefano","year":"2026","journal-title":"Transfusion"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1111\/trf.18047","article-title":"It is time to reconsider leukoreduction of whole blood for use in patients with life-threatening hemorrhage","volume":"64","author":"Yazer","year":"2024","journal-title":"Transfusion"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/military-2024-002835","article-title":"\u2018Golden day\u2019 is a myth: Rethinking medical timelines and risk in large scale combat operations","volume":"172","author":"Dilday","year":"2026","journal-title":"BMJ Mil. Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e71810","DOI":"10.1002\/cam4.71810","article-title":"Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population","volume":"15","author":"Robins","year":"2026","journal-title":"Cancer Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5327\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:49:42Z","timestamp":1783532982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":21,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145327"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145327","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}